In 2020, we launched the Lilly Insulin Value Program—allowing anyone eligible to purchase their monthly prescription of Lilly insulin for $35 or less. Now, we’re announcing updates that make accessing $35-a-month* Lilly insulin even easier, including:

Through the Lilly Insulin Value Program, all Lilly insulins are available for $35 a month whether you have commercial insurance or no insurance. These savings cover all Lilly insulins. * Terms and conditions apply. At retail pharmacies.

Today, we’re researching and developing technologies that could improve insulins, and innovating in digital connected care solutions for better treatment management. We’re also committed to helping people with diabetes get the medicine they need through our insulin access programs.

INDIANAPOLIS, March 1, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced price reductions of 70% for its most commonly prescribed insulins and an expansion of its Insulin Value Program that caps patient out-of-pocket costs at $35 or less per month.

Lilly has produced insulins for over 100 years and remains committed to advancing solutions to improve treatment and help patients access, afford and administer insulin therapies.

Humalog mealtime insulins are used to treat people with type 1 or type 2 diabetes for the control of high blood sugar. Humalog is a rapid-acting insulin that starts working faster and works for a shorter period of time than regular (short-acting) insulin.

Learn more about Lyumjev, a fast-acting mealtime insulin indicated to treat adults and children with diabetes for the control of high blood sugar.

Update on Humalog® (insulin lispro injection) and Insulin Lispro Injection 10mL Vial. We understand how vital insulin is to the patients who rely on it and take our responsibility to supply these medicines seriously.